ECMO-assisted valve-in-valve transcatheter aortic valve replacement following surgical aortic valve replacement failure in triple-positive antiphospholipid syndrome and systemic lupus erythematosus-associated libman-sacks endocarditis: a case report

BACKGROUND: Libman-Sacks endocarditis (LSE) is a non-infective valvular manifestation of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), affecting 15-30% of patients with APS. Characterized by sterile vegetations predisposing to thromboembolism and valvular dysfunction, optimal anticoagulation and intervention strategies remain challenging, particularly with rapid prosthetic failure. CASE PRESENTATION: A 63-year-old African American man with a 20-year history of SLE and triple-positive APS presented with cardiogenic shock five months after surgical aortic valve replacement (SAVR) for LSE. Echocardiography revealed severe bioprosthetic obstruction (mean gradient 79.6 mmHg, valve area 0.30 cm²). Given prohibitive redo surgical risk (STS-PROM 18.2%), he underwent ECMO-assisted valve-in-valve transcatheter aortic valve replacement (TAVR) with a 26 mm Edwards SAPIEN 3 valve. Left ventricular ejection fraction improved from 25-29% to 55-59% at 4.5 months, sustained at 50-54% at 8-month follow-up. He remained stable on warfarin (INR 2-3), hydroxychloroquine, and rituximab under multidisciplinary care. DISCUSSION: This case demonstrates diagnostic challenges differentiating LSE from bioprosthetic valve thrombosis (BPVT); a competing diagnosis that could not be excluded without histopathologic confirmation, critical limitations of DOACs in triple-positive APS, and feasibility of ECMO-supported TAVR as an exceptional rescue strategy. Rituximab was administered for refractory APS, though its independent contribution to the favorable outcome cannot be determined. CONCLUSION: To our knowledge, this is the first reported ECMO-assisted valve-in-valve TAVR following SAVR failure in APS/SLE-associated LSE. It emphasizes multidisciplinary care, warfarin-based anticoagulation, immunosuppression escalation, and long-term surveillance for complex autoimmune valvular disease.

Authors

Institutions

Publication Details

Journal
The Egyptian Heart Journal
Published
2026-11-16
DOI
https://doi.org/10.1186/s43044-026-00794-9
Primary Topic
Cardiac Valve Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ECMO-assisted valve-in-valve transcatheter aortic valve replacement following surgical aortic valve replacement failure in triple-positive antiphospholipid syndrome and systemic lupus erythematosus-associated libman-sacks endocarditis: a case report

Nazaradden Ibrahim, Hiba Fala, Abboud Batri, Stephanie Ammari
2 links
The Egyptian Heart Journal
Cardiac Valve Diseases and Treatments
article

ECMO-assisted valve-in-valve transcatheter aortic valve replacement following surgical aortic valve replacement failure in triple-positive antiphospholipid syndrome and systemic lupus erythematosus-associated libman-sacks endocarditis: a case report

Nazaradden Ibrahim, Hiba Fala, Abboud Batri, Stephanie Ammari
article en

Abstract

BACKGROUND: Libman-Sacks endocarditis (LSE) is a non-infective valvular manifestation of systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS), affecting 15-30% of patients with APS. Characterized by sterile vegetations predisposing to thromboembolism and valvular dysfunction, optimal anticoagulation and intervention strategies remain challenging, particularly with rapid prosthetic failure. CASE PRESENTATION: A 63-year-old African American man with a 20-year history of SLE and triple-positive APS presented with cardiogenic shock five months after surgical aortic valve replacement (SAVR) for LSE. Echocardiography revealed severe bioprosthetic obstruction (mean gradient 79.6 mmHg, valve area 0.30 cm²). Given prohibitive redo surgical risk (STS-PROM 18.2%), he underwent ECMO-assisted valve-in-valve transcatheter aortic valve replacement (TAVR) with a 26 mm Edwards SAPIEN 3 valve. Left ventricular ejection fraction improved from 25-29% to 55-59% at 4.5 months, sustained at 50-54% at 8-month follow-up. He remained stable on warfarin (INR 2-3), hydroxychloroquine, and rituximab under multidisciplinary care. DISCUSSION: This case demonstrates diagnostic challenges differentiating LSE from bioprosthetic valve thrombosis (BPVT); a competing diagnosis that could not be excluded without histopathologic confirmation, critical limitations of DOACs in triple-positive APS, and feasibility of ECMO-supported TAVR as an exceptional rescue strategy. Rituximab was administered for refractory APS, though its independent contribution to the favorable outcome cannot be determined. CONCLUSION: To our knowledge, this is the first reported ECMO-assisted valve-in-valve TAVR following SAVR failure in APS/SLE-associated LSE. It emphasizes multidisciplinary care, warfarin-based anticoagulation, immunosuppression escalation, and long-term surveillance for complex autoimmune valvular disease.

The Egyptian Heart JournalVol. 78(1)
HCA Healthcare (US)
Good health and well-being
Cardiac Valve Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon